Translational Research Laboratory Prof. C. A. Hart (IMIP), Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
Department of Oncology Surgery, Hospital de Cancer de Pernambuco, Recife, Brazil.
J Surg Oncol. 2022 Jul;126(1):139-143. doi: 10.1002/jso.26856.
Previous studies demonstrated an association between OX40+T cell expression with poor prognosis in gastric cancer (GC). The soluble form of OX40 (sOX40) could block the interactions between OX40 on the effector T cell, and it is a ligand (OX40L) in dendritic cells. However, the role of sOX40 as a pretreating biomarker and prognostic predictor remains unclear. This study aimed to evaluate the association of levels of sOX40 and sOX40L with disease progression in GC.
Between 2017 and 2018, a cross-sectional study was performed on 83 GC patients and 20 healthy controls.
Among 83 GC patients (median of 63 years), 32.4% of patients with I/II stages, 42.3% III, and 25.3% in IV stages. Metastatic GC patients had significantly higher levels of soluble OX40 compared with stage III (p = 0.0003) and early stages I and II patients (p = 0.005). There was no significant differences in the sOX40 and sOX40L levels between Lauren's histological subtype (intestinal, diffuse, and mixed).
This study showed that soluble OX40 levels have an essential role in GC progression. OX40 molecules may constitute a predictor for poor prognosis and a potential target for immunotherapy in GC.
先前的研究表明，OX40+T 细胞的表达与胃癌（GC）的预后不良有关。OX40 的可溶性形式（sOX40）可以阻断效应 T 细胞上 OX40 与树突状细胞之间的相互作用，是其配体（OX40L）。然而，sOX40 作为预处理生物标志物和预后预测因子的作用仍不清楚。本研究旨在评估 sOX40 和 sOX40L 的水平与 GC 疾病进展的关系。
2017 年至 2018 年，对 83 例 GC 患者和 20 名健康对照者进行了横断面研究。
在 83 例 GC 患者中（中位年龄 63 岁），I/II 期患者占 32.4%，III 期占 42.3%，IV 期占 25.3%。转移性 GC 患者可溶性 OX40 的水平明显高于 III 期（p=0.0003）和 I、II 期早期患者（p=0.005）。Lauren 组织学亚型（肠型、弥漫型和混合型）之间的 sOX40 和 sOX40L 水平无显著差异。
本研究表明，可溶性 OX40 水平在 GC 进展中具有重要作用。OX40 分子可能构成 GC 预后不良的预测因子和免疫治疗的潜在靶点。
